The UK Center of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK CERSI-PGx), led by the University of Liverpool, has published its first clinical guideline focused on the use ...

Most antidepressants are metabolized through the cytochrome P (CYP) 450 pathway; therefore, most drug metabolism genes on pharmacogenetic testing panels are related to CYP450 oxidase enzyme subunits.

Add Yahoo as a preferred source to see more of our stories on Google. Vince Fleming/Unsplash Finding an effective antidepressant can be as hit-or-miss as finding a drinkable cappuccino in a strip mall ...

This study explored patients' and healthcare professionals' views and knowledge of pharmacogenetic testing and associated future service development. Patients and healthcare professionals discussed ...

The treatment of clinical depression presents unique challenges, with many patients voicing concerns that echo a disheartening struggle: "I have tried every medication for depression, and nothing ...

UCSF is the first California facility and among about 10 in the nation to offer these tests, according to a May 4 news release from the San Francisco-based hospital. With the program, patients will ...

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage ...

Beginning May 9, UC San Francisco will be the first hospital in California, and one of only a few nationwide, to offer pharmacogenetic testing. The test will provide critical clues about a patient's ...

Add Yahoo as a preferred source to see more of our stories on Google. Genetic testing can help take the guesswork out of finding the right treatment. For certain diseases. To an extent. Winter ...

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType (TM) Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians ...

Thermo Fisher Scientific (NYSE:TMO) launched its TacroType Pharmacogenetic Test for transplant patients. The test is designed to support more personalized tacrolimus dosing based on a patient's ...